Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:50 pm Sale | 2024-05-30 | 13G | Inhibrx Biosciences, Inc. INBX | Perceptive Advisors LLC | 0 0.000% | -4,776,306 (Position Closed) | Filing History |
| 2024-06-03 5:56 pm Sale | 2024-05-30 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 0 0.000% | -7,150,826 (Position Closed) | Filing History |
| 2024-02-14 5:09 pm Sale | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Kayyem Jon Faiz | 3,308,123 7.000% | -97,686 (-2.87%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | RA CAPITAL MANAGEMENT L.P. | 4,724,352 9.990% | 870,485 (+22.59%) | Filing History |
| 2024-02-14 4:51 pm Purchase | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Perceptive Advisors LLC | 4,776,306 9.900% | 1,462,523 (+44.13%) | Filing History |
| 2024-02-14 4:16 pm Purchase | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Lappe Mark | 3,184,508 6.700% | 34,794 (+1.10%) | Filing History |
| 2024-02-14 4:12 pm Sale | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Eckelman Brendan P. | 2,397,219 5.100% | -352,734 (-12.83%) | Filing History |
| 2024-02-14 10:00 am Purchase | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 7,150,826 15.100% | 511,627 (+7.71%) | Filing History |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | BlackRock Inc. BLK | 2,715,672 5.700% | 299,484 (+12.39%) | Filing History |
| 2024-01-23 10:10 am Sale | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | STATE STREET CORP STT | 1,635,726 3.460% | -871,262 (-34.75%) | Filing History |
| 2023-03-08 6:00 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Inhibrx Inc. INBX | 3,147,235 7.200% | 650,849 (+26.07%) | Filing History |
| 2023-03-08 6:00 pm Sale | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Inhibrx Inc. INBX | 2,496,386 5.700% | -810,924 (-24.52%) | Filing History |
| 2023-03-08 5:59 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Inhibrx Inc. INBX | 3,307,310 7.600% | 995,855 (+43.08%) | Filing History |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | RA CAPITAL MANAGEMENT L.P. | 3,853,867 8.900% | 668,036 (+20.97%) | Filing History |
| 2023-02-14 2:35 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Perceptive Advisors LLC | 3,313,783 7.600% | 1,345,039 (+68.32%) | Filing History |
| 2023-02-14 1:18 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 6,639,199 15.200% | 1,333,333 (+25.13%) | Filing History |
| 2023-02-08 2:02 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | STATE STREET CORP STT | 2,506,988 5.760% | 2,506,988 (New Position) | Filing History |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | BlackRock Inc. BLK | 2,416,188 5.500% | 2,416,188 (New Position) | Filing History |
| 2022-10-17 5:21 pm Purchase | 2022-10-07 | 13G | Inhibrx Biosciences, Inc. INBX | RA CAPITAL MANAGEMENT L.P. | 3,185,831 8.160% | 3,185,831 (New Position) | Filing History |
| 2022-07-18 8:59 pm Purchase | 2022-07-05 | 13G | Inhibrx Biosciences, Inc. INBX | Perceptive Advisors LLC | 1,968,744 5.000% | 1,968,744 (New Position) | Filing History |